Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

A multi center comparative study of impulse control disorder in Latin American patients with Parkinson disease

  • Carolina Candelaria Ramírez Gómez
  • , Marcos Serrano Dueñas
  • , Oscar Bernal
  • , Natalia Araoz
  • , Michel Sáenz Farret
  • , Victoria Aldinio
  • , Verónica Montilla
  • , Federico Micheli*
  • *Autor correspondiente de este trabajo

Producción científica: RevistaArtículorevisión exhaustiva

Resumen

Objectives: Impulse control disorder (ICD) is a common adverse effect in patients with Parkinson disease who receive dopamine agonists; however, other factors are involved in itsmanifestations. To study the frequency and factors involved in the development of this adverse effect in a Latin American population, we conducted a cross-sectional multicenter study. Methods: Two hundred fifty-five patients in 3 Latin American centers were evaluated by examination and application of scales (Unified Parkinson's Disease Rating Scale, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale, Hoehn and Yahr, Clinical Impression of Severity Index for Parkinson's Disease). Results: Of the patients, 27.4% had ICD, most of whom were on dopamine agonists. Other associated risk factors included a younger age at onset of Parkinson disease, moderate symptoms, a shorter evolution of the clinical manifestations, rapid eye movement (REM) sleep disorder behavior, and the consumption of tea, mate, and alcohol. Conclusions: The frequency of ICD is higher in Latin America than in Anglo-Saxon populations. Consuming tea and mate, in addition to the use of dopamine agonists, is a factor that may demonstrate a genetic link that predisposes patients to the establishment of an ICD.

Idioma originalInglés
Páginas (desde-hasta)51-55
Número de páginas5
PublicaciónClinical Neuropharmacology
Volumen40
N.º2
DOI
EstadoPublicada - 2017

Nota bibliográfica

Publisher Copyright:
© Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved.

Citar esto